TARA - Long Setup Possible entry above 7.32, Stop signal 5.93., First target 8.37, 2nd target momentum. Strong insider buyingLongby AcornWealthCorp1
$TARA lets go whale hunting*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Early this morning 2 of my teams 20 holdings hit their set stop losses. The entire market practically wet the bed this morning but this small dip is nothing new to us, we have seen far worst before. $BABA and $GORO were the tickers that disappointed us this morning. We set stop losses for good reason and normally move on once they are reached. My team believes that $BABA and $GORO are still good holdings, but we're not looking at new entries for the near future. Like many of you have probably already guessed, my team does not disclose all of our holdings on trading view. Some of these disclosed holdings are what we @SimplyShowMeTheMoney refer to as platinum grade picks. Regardless we're generous people, and want to share with you one of our big dogs... Today my team is introducing biotech company $TARA (Artara Therapeutics). $TARA is committed to advancing transformative therapies for people with rare and specialty diseases (such as cancer). Earnings are expected on 7/30/21. My team expects little good news for lift off thanks to the massive sell off that $TARA has experienced. My team entered $TARA on 7/6/21 at $8.70 per share. If you want to see more, please like and follow us @SimplyShowMeTheMoney Longby SimplyShowMeTheMoney4
Protara Therapeutics Inc π§Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). If you want not to miss ideas like this one,π― subscribe and press a thumb up! π Have a question? Don't be shy to ask! π€ Interested to study how to analyze charts, follow me! Longby unfair_advantage226
TARA - Long Setup Looking to break 18.03. Stop signal 15.43. First target 24.73Longby AcornWealthCorp0
TARA Technical Analysis π§Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). If you understand the idea,π― press a thumb up! π Have a question? Don't be shy to ask! π€ Interested to study how to analyze charts, follow me! Longby unfair_advantage2